Back to results
US 6,583,180 B2Granted
Glucocorticoid receptor modulators
AssigneeAbbott Laboratories
InventorsJames T. Link, Bryan K. Sorensen, Jyoti R. Patel, David L. Arendsen, Gaoquan Li
Life of this patent
Estimating the term…
Abstract
Compounds of formula (I) or pharmaceutically acceptable salts thereof are novel glucocorticoid receptor modulators and are useful for treating type II diabetes in a mammal.
Claims75
A compound having formula (I)
- or a pharmaceutically acceptable salt or prodrug thereof, wherein
- LA is a covalent bond or C(XA1)(XA2);
- LD is a covalent bond or C(XD1)(XD2);
- XA1 is selected from the group consisting of hydrogen, alkoxy, alkoxycarbonyl, alkoxyalkyl, alkyl, alkylcarbonyl, cyano, halogen, hydroxy, hydroxyalkyl, nitro and (NR10R11)carbonyl;
- XA2 is selected from the group consisting of hydrogen and alkyl;
- or XA1 and XA2 together are oxo;
- XD1 is selected from the group consisting of hydrogen, alkoxy, alkoxycarbonyl, alkoxyalkyl, alkyl, alkylcarbonyl, cyano, halogen, hydroxy, hydroxyalkyl, nitro and (NR10R11)carbonyl;
- XD2 is selected from the group consisting of hydrogen and alkyl;
- or XD1 and XD2 together are oxo;
- LB is absent or selected from the group consisting of a covalent bond, alkenylene, alkylene, alkynylene, —(CH2)mC(O)(CH2)n—, —(CH2)mC(O)(CH2)nCH═CH—, —(CH2)mC(O)(CH2)nC═C—, —(CH2)mCH(OH)(CH2)n—, —(CH2)mCH(OH)(CH2)nCH2CH≡CH—, —(CH2)mCH(OH)(CH2)nCH2C≡C—, —(CH2)mO(CH2)n—, —(CH2)mO(CH2)nCH2CH═CH—, —(CH2)mO(CH2)nCH2C≡C—, —(CH2)mS(CH2)n—, —(CH2)mS(O)(CH2)n—, —(CH2)mS(O)2(CH2)n—, —(CH2)mN(R7)(CH2)n—, —(CH2)mN(R7)C(O)(CH2)n—, —(CH2)mC(O)N(R7)(CH2)n—, —O(CH2)mC(O)N(R7)(CH2)n—, CH2)mC(O)O(CH2)n—, —O(CH2)mC(O)(CH2)n—, —(CH2)mN(R7)S(O)2(CH2)n—, —(CH2)mS(O)2N(R7)(CH2)n—, —(CH2)mS(O)2O(CH2)n— and —(CH2)mOS(O)2(CH2)n— wherein each group is inserted as drawn with the left end attached to A and the right end attached to B;
- m is an integer of 0-6;
- n is an integer of 0-6;
- LC is absent or selected from the group consisting of a covalent bond, alkenylene, alkylene, alkynylene, —(CH2)pC(O)(CH2)q—, —(CH2)pC(O)(CH2)qCH═CH—, —(CH2)pC(O)(CH2)qC≡C—, —(CH2)pCH(OH)(CH2)q—, —(CH2)pCH(OH)(CH2)qCH2CH═CH—, —(CH2)pCH(OH)(CH2)qCH2C≡C—, —(CH2)pO(CH2)q—, —(CH2)pO(CH2)qCH2CH═CH—, —(CH2)pO(CH2)qCH2C≡C—, —(CH2)pS(CH2)q—, —(CH2)pS(O)(CH2)q—, —(CH2)pS(O)2(CH2)q—, —(CH2)pN(R7)(CH2)q—, —(CH2)pN(R7)C(O)(CH2)q—, —(CH2)pC(O)N(R7)(CH2)q—, —O(CH2)pC(O)N(R7)(CH2)q—, —(CH2)pC(O)O(CH2)q—, —O(CH2)pC(O)(CH2)q—, —(CH2)pN(R7)S(O)2(CH2)q—, —(CH2)pS(O)2N(R7)(CH2)q—, —(CH2)pS(O)2O(CH2)q— and —(CH2)pOS(O)2(CH2)q— wherein each group is inserted as drawn with the left end attached to B and the right end attached to C;
- p is an integer of 0-6;
- q is an integer of 0-6;
- LE is absent or selected from the group consisting of a covalent bond, alkenylene, alkylene, alkynylene, —(CH2)rC(O)(CH2)s—, —(CH2)rC(O)(CH2)sCH═CH—, —(CH2)rC(O)(CH2)sC≡C—, —(CH2)rCH(OH)(CH2)s—, —(CH2)rCH(OH)(CH2)sCH2CH═CH—, —(CH2)rCH(OH)(CH2)sCH2C≡C—, —(CH2)rO(CH2)s—, —(CH2)rO(CH2)sCH2CH═CH—, —(CH2)rO(CH2)sCH2C≡C—, —(CH2)rS(CH2)s—, —(CH2)rS(O)(CH2)s—, —(CH2)rS(O)2(CH2)s—, —(CH2)rN(R7)(CH2)s—, —(CH2)rN(R7)C(O)(CH2)s—, —(CH2)rC(O)N(R7)(CH2)s—, —O(CH2)rC(O)N(R7)(CH2)s—, —(CH2)rC(O)O(CH2)s—, —O(CH2)rC(O)(CH2)s—, —(CH2)rN(R7)S(O)2(CH2)s—, —(CH2)rS(O)2N(R7)(CH2)s—, —(CH2)rS(O)2O(CH2)s— and —(CH2)rOS(O)2(CH2)s— wherein each group is inserted as drawn with the left end attached to D and the right end attached to E;
- r is an integer of 0-6;
- s is an integer of 0-6;
- LE is absent or selected from the group consisting of a covalent bond, alkenylene, alkylene, alkynylene, —(CH2)uC(O)(CH2)v—, —(CH2)uC(O)(CH2)vCH═CH—, —(CH2)uC(O)(CH2)vC≡C—, —(CH2)uCH(OH)(CH2)v—, —(CH2)uCH(OH)(CH2)vCH2CH═CH—, —(CH2)uCH(OH)(CH2)vCH2C≡C—, —(CH2)uO(CH2)v—, —(CH2)uO(CH2)vCH2CH═CH—, —(CH2)uO(CH2)vCH2C≡C—, —(CH2)uS(CH2)v—, —(CH2)uS(O)(CH2)v—, —(CH2)uS(O)2(CH2)v—, —(CH2)uN(R7)(CH2)v—, —(CH2)uN(R7)C(O)(CH2)v—, —(CH2)uC(O)N(R7)(CH2)v—, —O(CH2)uC(O)N(R7(CH2)v—, —(CH2)uC(O)O(CH2)v—, —O(CH2)uC(O)(CH2)v—, —(CH2)uN(R7)S(O)2(CH2)v—, —(CH2)uS(O)2N(R7)(CH2)v—, —(CH2)uS(O)2O(CH2)v— and —(CH2)uOS(O)2(CH2)v— wherein each group is inserted as drawn with the left end attached to E and the right end attached to F;
- u is an integer of 0-6;
- v is an integer of 0-6;
- A and D are each independently selected from the group consisting of aryl, cycloalkyl and heterocycle;
- B, C, F and F are each independently absent or each independently selected from the group consisting of aryl, cycloalkyl and heterocycle;
- RA1, RA2, RA3, RA4, RA5, RB1, RB2, RB3, RB4, RB5, RC1, RC2, RC3, RC4, RC5, RD1, RD2, RD3, RD4, RD5, RE1, RE2, RE3, RE4, RE5, RF1, RF2, RF3, RF4 and RF5 are each independently absent or each independently selected from the group consisting of hydrogen, alkenyl, alkenylthio, alkenyloxy, alkoxy, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxyalkoxyalkyl, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkoxy, alkoxycarbonylalkyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonylalkoxy, alkylcarbonylalkyl, alkylcarbonylalkylthio, alkylcarbonyl(NR11)sulfonylalky, alkylcarbonyloxy, alkylcarbonylthio, alkylsulfinyl, alkylsulfinylalkyl, alkylsulfonyl, alkylsulfonylalkyl, alkylsulfonyl(NR10)carboxylalkyl, alkylsulfonyl(NR10)carboxylalkoxy, alkylsulfonyl(NR10)alkyl(NR11)—, alkylthio, alkylthioalkyl, alkylthioalkoxy, alkynyl, alkynyloxy, alkynylthio, carboxy, carboxyalkoxy, carboxylalkoxyalkoxy, carboxyalkyl, cyano, cyanoalkoxy, cyanoalkyl, cyanoalkylthio, cycloalkylalkoxy, cycloalkyloxy, ethylenedioxy, formyl, formylalkoxy, formylalkyl, haloalkenyl, haloalkenyloxy, haloalkoxy, haloalkyl, haloalkynyl, haloalkynyloxy, halogen, hydroxy, hydroxyalkoxy, hydroxyalkyl, mercapto, mercaptoalkoxy, mercaptoalkyl, methylenedioxy, nitro, —NR8R9, (NR8R9)alkoxy, (NR8R9)alkyl, (NR8R9)carbonyl, (NR8R9)carbonylalkoxy, (NR8R9)carbonylalkyl, (NR10R11)sulfonyl, (NR10R11)sulfonylalkyl, —NR10S(O)2R12, —NR10S(O)2NR13R14, and —S(O)2OH;
- R1, R2, and R3 are each independently selected from the group consisting of hydrogen, alkoxycarbonyl, alkoxy, alkoxyalkyl, alkyl, alkylcarbonyl, carboxy, halogen, hydroxyalkyl, —NR10R11 and (NR10R11)alkyl;
- R4 is selected from the group consisting of alkenyl, alkoxy, alkoxyalkenyl, alkoxyalkoxy, alkoxyalkyl, alkoxyalkynyl, alkoxycarbonyl, alkoxycarbonylalkoxy, alkoxycarbonylalkenyl, alkoxycarbonylalkyl, alkoxycarbonylalkynyl, alkyl, alkylcarbonyl, alkylcarbonylalkenyl, alkylcarbonylalkoxy, alkylcarbonylalkyl, alkylcarbonylalkynyl, alkynyl, carboxy, carboxyalkenyl, carboxyalkyl, carboxyalkynyl, haloalkoxy, haloalkyl, haloalkenyl, haloalkynyl, halogen, hydroxyalkyl, —NR10R11, (NR10R11)alkyl, (NR10R11)carbonyl, (NR10R11)carbonylalkyl, (NR10R11)carbonylalkenyl and (NR10R11)carbonylalkynyl;
- R5 is selected from the group consisting of hydrogen and alkyl;
- R6 is selected from the group consisting of hydrogen, alkoxycarbonyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylsulfonyl, arylalkoxycarbonyl, arylalkylcarbonyl, arylalkylsulfonyl, arylcarbonyl, arylsulfonyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl, cycloalkylsulfonyl, cycloalkylalkylsulfonyl, heterocyclecarbonyl, heterocyclealkylcarbonyl, heterocyclesulfonyl, heterocyclealkylsulfonyl, (NR13R14)carbonyl and (NR13R14)sulfonyl;
- R8 and R9 are each independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylsulfonyl, alkynyl, carboxyalkylcarbonyl;
- cyanoalkyl, formyl, hydroxy, hydroxyalkyl, —NR10R11, (NR10R11)carbonyl and carboxyalkyl wherein the alkyl portion of carboxyalkyl is optionally substituted with one or two substituents selected from the group consisting of alkylthio, aryl, heterocycle, hydroxy, carboxy, —NR10R11 and (NR10R11)carboxy;
- R10 and R11 are each independently selected from the group consisting of hydrogen and alkyl;
- R12 is selected from the group consisting of alkoxy, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle and heterocyclealkyl;
- and
- R13 and R14 are each independently selected from the group consisting of hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle and heterocyclealkyl.
31 more elements
A method of treating type II diabetes in a mammal comprising administering a therapeutically effective amount of a glucocorticoid receptor antagonist.
Dependencies are inferred from the claim text.